Navigation Links
Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
Date:9/16/2013

ATLANTA, Sept. 16, 2013 /PRNewswire/ -- Atlanta-based pharmaceutical discovery and development company, Celtaxsys, Inc., announced today the achievement of a significant clinical milestone for its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease. Celtaxsys has successfully completed the first of two clinical trials in its Phase 1 program, and the first trial conducted through its Australia subsidiary, Celtaxsys Aus Pty Ltd. In this First-in-Human trial, CTX-4430 was administered orally to Healthy Volunteers in escalating doses (up to 200 mg/day for 2 weeks) and was well-tolerated at all doses. Results of the trial will be presented at the 27th Annual North American Cystic Fibrosis Conference in October.

"This was a robust First-in-Human clinical trial assessing safety in 96 subjects. We're very pleased with the safety outcomes of CTX-4430 in this Healthy Volunteer study," said Dr. Ed Philpot, Celtaxsys CMO.  "These results support the continued clinical development of CTX-4430 as a once-daily oral treatment for pulmonary inflammation in CF."

CTX-4430 also exhibited excellent pharmacokinetic and pharmacodynamic properties in this study. "The 100 mg dose achieved maximal effect on its intended target, Leukotriene A4 Hydrolase, for the entire 24 hour period between doses," said Dr. Eric Springman, Celtaxsys CSO. "Having a biomarker to directly probe mechanism of action provides us with a much better understanding of the relationship between dose and effect and will be a tremendous help in the further clinical development of CTX-4430."

Said Mr. Ralph Grosswald, VP of Operations at Celtaxsys, "We had a great experience conducting our initial Phase 1 study of CTX-4430 in Australia. The entire process from start to finish was very efficient and the facilities were second to none."

CTX-4430 will now progress into a Phase 1B trial to assess the safety and pharmacokinetics of once-daily oral treatment for lung disease in Cystic Fibrosis patients.

About Cystic Fibrosis: Cystic Fibrosis is the most common life-shortening autosomal recessive disease among Caucasians, and lung disease is the leading cause of hospitalizations and death in adult CF patients. A hallmark of CF lung disease is excessive recruitment of blood polymorphonuclear neutrophils (PMNs) into the small airways (bronchioles) causing inflammation that results in elastic tissue destruction and progressive loss of lung function.

About CTX-4430: CTX-4430 is a once-daily oral drug candidate currently undergoing clinical trials for treatment of CF lung disease. It is a novel small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the key enzyme in production of the potent inflammatory mediator Leukotriene B4 (LTB4). LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in CF.

About Celtaxsys: Celtaxsys is a privately-held clinical stage drug discovery and development company focused on developing new treatments for inflammatory diseases by modulating innate immunity. The company is building a sustainable pipeline of first-in-class drugs with novel mechanisms of action. For more information, please visit www.celtaxsys.com.


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Celtaxsys Restructures, Enhances Operational Focus
2. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
3. Plastic Surgeon Dr. Marc J. Salzman Announces Use of Astanza Trinity Laser Tattoo Removal System, Runs Limited-Time Promotion
4. Sam Solakyan announces Paramount Management Services is now a full-scale MSO
5. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
6. Cell Therapeutics Announces Sale of Convertible Preferred Stock
7. Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
8. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
9. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
10. Egalet Announces Financing to Fund Abuse-Deterrent Medications
11. PRA Holdings Announces Proposed Private Offering of $375 Million Senior Notes Due 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... Feb. 23, 2017 Non-alcoholic steatohepataitis ... the various drugs being developed for the ... the drugs that are in various phases ... pipeline focuses on novel pharmacologic drugs & ... cell therapies, recombinant proteins and RNA-based therapeutics, ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby ... America, today announced it would be offering some it’s exclusive product line to ... crafting quality and unique baby clothing/feeding products, will team up with AMAZON to ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in persons with a specific LRRK2 mutation, according to a study released today ... have provided evidence of a link between pesticides and incidence of sporadic PD ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... it is so critically important that we all are aware of our options ... Mediaplanet is proud to announce the launch of its newest edition of "Vision ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
Breaking Medicine News(10 mins):